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Abstract
Introduction Mild therapeutic hypothermia has been shown to
improve outcome for patients after cardiac arrest and may be
beneficial for ischaemic stroke and myocardial ischaemia
patients. However, in the awake patient, even a small decrease
of core temperature provokes vigorous autonomic reactions–
vasoconstriction and shivering–which both inhibit efficient core
cooling. Meperidine and skin warming each linearly lower
vasoconstriction and shivering thresholds. We tested whether a
combination of skin warming and a medium dose of meperidine
additively would reduce the shivering threshold to below 34°C
without producing significant sedation or respiratory
depression.
Methods Eight healthy volunteers participated on four study
days: (1) control, (2) skin warming (with forced air and warming
mattress), (3) meperidine (target plasma level: 0.9 μg/ml), and
(4) skin warming plus meperidine (target plasma level: 0.9 μg/
ml). Volunteers were cooled with 4°C cold Ringer lactate
infused over a central venous catheter (rate ≈ 2.4°C/hour core
temperature drop). Shivering threshold was identified by an
increase of oxygen consumption (+20% of baseline). Sedation
was assessed with the Observer's Assessment of Alertness/
Sedation scale.
Results Control shivering threshold was 35.5°C ± 0.2°C. Skin
warming reduced the shivering threshold to 34.9°C ± 0.5°C (p
= 0.01). Meperidine reduced the shivering threshold to 34.2°C
± 0.3°C (p < 0.01). The combination of meperidine and skin
warming reduced the shivering threshold to 33.8°C ± 0.2°C (p
< 0.01). There were no synergistic or antagonistic effects of
meperidine and skin warming (p = 0.59). Only very mild sedation
occurred on meperidine days.
Conclusion A combination of meperidine and skin surface
warming reduced the shivering threshold to 33.8°C ± 0.2°C via
an additive interaction and produced only very mild sedation and
no respiratory toxicity.
Introduction
Considerable evidence in animals indicates that mild hypo-
thermia provides substantial protection against cerebral [1-4]
and myocardial [5,6] ischaemia. In humans, mild hypothermia
has been shown to improve neurologic outcome and to reduce
mortality after cardiac arrest [7,8].
Mild hypothermia with core temperatures between 33°C and
34°C is relatively easy to induce during general anaesthesia
because anaesthetics profoundly impair thermoregulatory
responses [9-12]. However, induction of mild hypothermia in
awake patients after acute myocardial infarction or acute
ischaemic stroke may be difficult. Minute reductions (> 0.2°C)
in core temperature trigger aggressive autonomic reactions–
namely, arteriovenous shunt vasoconstriction and shivering–
which per se impair efficient core cooling. Consequently, to
lower the vasoconstriction and shivering thresholds, numerous
studies have searched for drugs and drug combinations,
including meperidine [13], buspirone [14], dexmedetomidine
[15], clonidine [16], nefopam [17], and several others. Further-
more, non-pharmacological treatments–arm and face warming
[18] or whole-body skin warming[19]–have been investigated
with regard to their impact on thermoregulatory thresholds.
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Meperidine, in contrast to other opioids, possesses additional
anti-shivering action at equianalgesic doses and inhibits shiv-
ering twice as much as vasoconstriction [13,20]. However,
when meperidine is used as a single drug, large plasma con-
centrations are needed to reduce the shivering threshold to
below 34°C. These high plasma concentrations can cause
significant respiratory depression and sedation and mandate
close patient monitoring in an intensive care environment.
They are thus not ideal in patient populations in which contin-
uous evaluation of neurologic functioning is a major diagnostic
and treatment approach.
In contrast, skin warming [19,21] efficiently lowers thermoreg-
ulatory thresholds without causing side effects. The skin con-
tributes approximately 20% to the control of each
thermoregulatory threshold [19,22], but skin surface warming
alone is not sufficient to allow induction of mild hypothermia
(33°C to 34°C) with catheter or intravenous fluid cooling.
However, a combination of skin surface warming and a
medium dose of meperidine (≈ 0.9 μg/ml plasma level) might
additively decrease the shivering threshold to below 34°C. We
therefore tested the hypothesis that the combination of mepe-
ridine and skin surface warming decreases the shivering
threshold to below 34°C via an additive interaction without
causing significant sedation or respiratory toxicity.
Materials and methods
After obtaining approval by the Institutional Review Board of
the University Hospital of Bern and written informed consent,
we studied eight healthy volunteers on four days. Morphomet-
ric characteristics were age of 23 ± 2 years, weight of 68.6 ±
9.4 kg, height of 177 ± 7.5 cm, and body mass index of 22 ±
2. The volunteers fasted eight hours before the experiment.
During treatment, they were minimally clothed and rested in a
supine position on a standard patient bed equipped with a
water mattress.
Treatment protocol
All experiments were started between 8:30 and 9:00 a.m. to
avoid any interference with thermoregulatory circadian fluctu-
ations. After arrival in the volunteer laboratory, volunteers were
randomly assigned to one of the four study days by means of
a computer-generated randomisation list:
1. Control day: Placebo infusion, no skin warming.
2. Skin warming: The skin surface was warmed with a forced-
air warming system (Bair Hugger; Arizant Inc., Eden Prairie,
MN, USA) and a circulating water mattress (Medi-Therm III;
Gaymar Industries, Inc., Orchard Park, NY, USA) set at maxi-
mum temperature (43°C and 41°C, respectively). Subse-
quently mean skin temperature was maintained at ≈ 35.8°C
throughout the study.
3. Meperidine (target plasma level: 0.9 μg/ml): Meperidine
was administered intravenously using an infusion regimen
based on previously published pharmacokinetic data [23,24].
4. Meperidine (target plasma level: 0.9 μg/ml) plus skin warm-
ing (forced air plus water mattress) as described above.
A central venous catheter was inserted in the volunteer's left
antecubital vein and used for blood sampling and infusion of
cold Ringer lactate. For meperidine administration, an intrave-
nous catheter was inserted into the right antecubital vein.
Once stable meperidine plasma levels and/or stable mean skin
temperature was established on each study day and active
arteriovenous shunt vasodilation was confirmed, lactated
Ringer solution cooled to ≈ 4°C was infused on all study days
at rates sufficient to decrease tympanic membrane tempera-
ture ≈ 2.4°C/hour (that is, ≈ 0.2°C every five minutes). The
core temperature cooling rate was restricted to less than
2.5°C/hour because this rate was unlikely to trigger any
dynamic thermoregulatory responses [25]. Fluid was given
until the shivering threshold was identified or a total of up to
80 ml/kg of fluid was administered. Each study day ended
upon detection of shivering. Subsequently, the volunteers
were warmed until they were comfortable and had recovered
from meperidine administration. Volunteers had an interval of
at least 48 hours between study days; before the start of treat-
ment, a blood sample was drawn to ensure that all meperidine
remaining from previous study days had been eliminated.
Measurements
Heart rate was measured continuously by means of an electro-
cardiogram, and blood pressure was determined using a non-
invasive method at 10 minute intervals at the left arm. Core
temperature was recorded from the tympanic membrane by
means of Mon-a-Therm® thermocouples (Mallinckrodt, Hazel-
wood, MO, USA). The tympanic probe was inserted by the vol-
unteers until they felt the thermocouple touch the tympanic
membrane; appropriate placement was confirmed when vol-
unteers detected gentle rubbing of the attached wire. Addi-
tionally, tympanic probes were inserted into both ears, and a
difference of less than or equal to 0.2°C confirmed correct
placement. The aural canal was occluded with cotton, the
probe was securely taped in place, and a gauze bandage was
positioned over the external ear. Mean skin surface tempera-
ture was determined from 15 area-weighted sites [26].
All temperatures were recorded from thermocouples con-
nected to calibrated Iso-Thermex® 16 channel electronic ther-
mometers (Columbus Instruments, Columbus, OH, USA) that
have an accuracy of 0.1°C and a precision of 0.01°C. Right
index fingertip blood flow was quantified using volume plethys-
mography [27]. All measures of flow were recorded at five-
minute intervals. Vasoconstriction threshold was defined by
the core temperature triggeringa fingertip flow of ≈ 1 ml/Available online http://ccforum.com/content/11/1/R29
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minute, which roughly corresponds to a forearm-minus-finger-
tip skin temperature gradient near 0°C and indicates mild
vasoconstriction [27].
Oxygen consumption was measured by a Vmax™ 29 n meta-
bolic monitor (SensorMedics Corporation, Yorba Linda, CA,
USA). Measurements were recorded every minute. A sus-
tained increase in oxygen consumption of 20% above baseline
identified the shivering threshold. The shivering and vasocon-
striction thresholds were determined post hoc by an investiga-
tor blinded to treatment and core temperature.
As in previous studies, the level of sedation was assessed
using the Observer's Assessment of Alertness/Sedation
(OAA/S) scale [28] (Table 1). Thermal comfort was evaluated
at 10-minute intervals with a 100 mm-long visual analogue
scale. Zero millimetres was defined as the worst imaginable
cold, 50 mm as thermal comfort, and 100 mm as the worst
imaginable heat. Both scores were obtained at 10-minute
intervals throughout cooling. Venous blood was sampled at
three time points: before the start of meperidine infusion (to
ensure that no meperidine plasma levels remained from previ-
ous study days) and at each thermoregulatory threshold for
measurement of meperidine plasma concentrations.
Meperidine plasma level analysis
Blood samples were centrifuged at 4°C (2,000 g, 30 minutes),
and the supernatant plasma was transferred to glass vials with
a screw cap and stored at -20°C until analysis. Prior to extrac-
tion, plasma samples were allowed to thaw at room tempera-
ture. To 0.2 ml of plasma, 200 ng of piperidolate (Sigma-
Aldrich, St. Louis, MO, USA) as internal standard (IS) and 0.05
ml 1 N sodium hydroxide solution were added and vortexed (5
seconds). Six tenths of a millilitre of a heptane-ethylacetate
mixture (1:1, vol/vol) was added and vortexed for 30 seconds.
The phases were separated by standing at room temperature
for three minutes and centrifugation (1,300 g, three minutes).
The water phase was flash-frozen in a 2-propanol dry ice bath.
The organic phase was decanted into a second tube and dried
under a gentle stream of nitrogen in a water bath (approxi-
mately 40°C). The residues were redissolved in 0.1 ml of
extraction mixture, and 1 μl was injected splitless into the gas-
chromatograph (Agilent 6890; Agilent Technologies, Inc.,
Santa Clara, CA, USA) equipped with a mass selective detec-
tor. The capillary column was a VF-Xms (Varian, Inc., Palo Alto,
CA, USA) with a length of 12 m, an inner diameter of 0.2 mm,
and a film thickness of 0.33 μm. The carrier gas was helium at
a flow rate of 1.0 ml/minute. Operating temperatures were
250°C for the injector, 280°C for the detector transfer line,
and 100°C for the oven, which increased (30°C/minute) to
300°C and was held at that temperature for six minutes. The
mass selective detector was operated in the electron impact
mode (70 eV) with selected ion monitoring with a dwell time of
100 ms. The data were processed with proprietary mass spec-
trometer control software (HP G1701AA). The ions for quan-
titation were m/z 247 for meperidine and m/z 165 for the IS.
Calibration curves with spiked and extracted plasma passed
through the origin and were linear in the calibration range of
0.4 to 3.2 μg/ml, and correlation coefficients were more than
0.98. Coefficients of variation (CVs) of intra-day reproducibility
(n = 5) were 3.1%, 3.2%, and 4.4% for meperidine in control
samples containing 2.1, 1.3, and 0.7 μg/ml, respectively. Intra-
day CVs were 3.5%, 3.6%, and 5.3% at the same concentra-
tions, respectively. The limit of quantitation at a signal-to-noise
ratio of 10:1 was 0.1 μg/ml. The recovery of meperidine and
IS was more than 98%.
Statistical analysis
Ambient temperature and physiological responses on each
study day were first averaged for each volunteer; data
obtained between the onset of shivering noticed by the
observer and clinically relevant shivering (oxygen consumption
+20%) were also included. The resulting values were then
averaged among volunteers. Data were tested for normal dis-
tribution by means of Q-Q plot and Shapiro-Wilk test. All data
were normally distributed. Results of the four study days and
meperidine levels were compared using the Friedman test and
the Student-Newman-Keuls test.
Interaction between the two treatments was evaluated using
analysis of variance for repeated measurements [29]. A signif-
Table 1
Observer's Assessment of Alertness/Sedation scale
Sub-score Responsiveness Speech Facial expression Eyes
5 Responds readily to name spoken in normal tone Normal Normal Clear, no ptosis
4 Lethargic response to name spoken in normal tone Mild slowing or thickening Mild relaxation Glazed or mild ptosis
3 Responds only after name is spoken loudly and/or repeatedly Slurring or prominent slowing Marked relaxation Glazed and marked ptosis
2 Responds only after mild prodding or shaking Few recognised words
1 Does not respond to mild prodding or shaking
The final score is the sum of the Responsiveness, Speech, Facial expression, and Eyes component scores. Thus, a 'wide awake' score = 20 and 
a 'deeply sedated' score = 9.Critical Care    Vol 11 No 1    Kimberger et al.
Page 4 of 7
(page number not for citation purposes)
icant interaction (antagonism or synergism) was indicated by
a statistically significant interaction term between the factors
'meperidine' and 'skin warming.' A non-significant interaction
term indicated an additive effect. All results are expressed as
means ± standard deviations; differences are considered sta-
tistically significant when p  is less than 0.05. SPSS 11.0
(SPSS Inc., Chicago, IL, USA) was used for statistical analy-
sis, and Graphpad Prism 4.0 (GraphPad Software, Inc., San
Diego, CA, USA) was used for figures.
Results
Physiological or ambient variables were comparable on the
four study days (Table 2). All volunteers were vasodilated
before the cold-fluid infusion was started. There was no differ-
ence for meperidine plasma levels between the meperidine
day and the meperidine plus skin warming day (p = 0.42), and
meperidine plasma levels remained stable throughout the
experiments. Meperidine produced only mild sedation; OAA/S
scale was not significantly decreased on the meperidine day
(p = 0.10, versus control) or the meperidine plus skin warming
day (p = 0.10, versus control) (Table 2).
Effect of meperidine and skin warming on the 
vasoconstriction threshold
Skin warming reduced the vasoconstriction threshold by -
0.4°C ± 0.3°C (p < 0.01). Meperidine reduced the vasocon-
striction threshold by -0.7°C ± 0.3°C (p < 0.01). The combi-
nation of meperidine and skin warming significantly reduced
the vasoconstriction threshold by -0.9°C ± 0.2°C (p < 0.01;
Table 2; all values compared to control day).
Effect of meperidine and skin warming on shivering 
threshold
Skin warming reduced the shivering threshold by -0.6°C ±
0.5°C (p = 0.01). Meperidine reduced the shivering threshold
by -1.3°C ± 0.3°C (p < 0.01). The combination of meperidine
and skin warming reduced the shivering threshold by -1.7°C ±
0.3°C (p < 0.01; Table 2; Figure 1; all values compared to
control day).
There was no interaction between meperidine and skin warm-
ing for vasoconstriction (p = 0.20) or shivering (p = 0.59)
thresholds. A combination of both treatments thus additively
reduced the shivering threshold.
Discussion
This study demonstrates that a combination of meperidine and
skin surface warming additively reduces the shivering thresh-
old to below 34°C and produces only very mild sedation and
no respiratory toxicity. The combination of meperidine and skin
surface warming can thus be recommended for facilitating the
application of therapeutic mild hypothermia in the awake
patient.
In humans, mild hypothermia for 24 hours has been shown to
improve outcome after cardiac arrest [7,8] and the application
of mild hypothermia has been advised by the International Liai-
son Committee on Resuscitation [30] and the European
Resuscitation Council [31]. Currently, several clinical mild
hypothermia studies in patients with ischaemic heart injury,
brain trauma, or ischaemic stroke are ongoing.
Table 2
Confounding factors and results
Control Skin warming Meperidine Combined
Ambient temperature (°C) 22.6 ± 0.46 22.3 ± 0.5 22.1 ± 0.7 22.3 ± 0.7
Mean arterial pressure (mm Hg) 89.3 ± 7.1 87.9 ± 10.9 87.8 ± 9.4 88.6 ± 5.4
Heart rate (beats per minute) 65.3 ± 7.8 67.9 ± 11.7 62.5 ± 8.2 69.4 ± 9.6
SpO2 (percentage) 99.3 ± 0.8 99.1 ± 0.6 98.6 ± 1.0 98.6 ± 0.9
PCO2 (mm Hg) 5.1 ± 0.3 5.1 ± 0.5 5.0 ± 0.4 5.2 ± 0.8
Ringer lactate (ml/kg) 22.0 ± 4.5 50.6 ± 13.0a 58.4 ± 12.8a 84.3 ± 6.8a
Meperidine (μg/ml) N/A N/A 0.98 ± 0.20 0.96 ± 0.19
Thermal comfort VAS 26.9 ± 5.0 28.9 ± 9.3 34.8 ± 8.6b 43.6 ± 9.6c
OAA/S scale 20 ± 0 19.9 ± 0.3 19.5 ± 0.7 19.4 ± 0.7
Mean skin temperature start (°C)d 35.7 ± 0.4 35.8 ± 0.3 35.8 ± 0.2 35.8 ± 0.2
Mean skin temperature end (°C)e 34.3 ± 0.7 35.6 ± 0.3a 33.8 ± 0.6 35.4 ± 0.3a
Core temperature vasoconstriction (°C) 36.5 ± 0.2 36.1 ± 0.2a 35.8 ± 0.3a 35.6 ± 0.3a
Core temperature shivering (°C) 35.5 ± 0.2 34.9 ± 0.5c 34.2 ± 0.3a 33.8 ± 0.2a
ap < 0.01, bp = 0.04, cp = 0.01 (versus control). dMean skin temperature measured immediately before intravenous cooling. eMean skin 
temperature measured at the end of cooling. N/A, not applicable; OAA/S: Observer's Assessment of Alertness/Sedation; PCO2, partial pressure 
of carbon dioxide; SpO2, oxygen saturation as measured by pulse oximetry; VAS, visual analogue scale.Available online http://ccforum.com/content/11/1/R29
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In the majority of clinical mild hypothermia studies, general
anaesthesia that patients received was often combined with
generous amounts of muscle relaxants to suppress shivering.
Although anaesthetics reduce shivering and vasoconstriction
thresholds by 2°C to 3°C, these drugs are, unsurprisingly, not
the first choice for induction of mild hypothermia in the awake
patient; they cause significant sedation and respiratory
depression and jeopardise airway patency.
Consequently, numerous studies have searched for other
drugs or drug combinations that lower vasoconstriction and
shivering thresholds. One of the most effective anti-shivering
drugs has proven to be meperidine [32,33]. Large plasma
concentrations of meperidine, when used as a single drug, are
necessary to reduce shivering thresholds to below 34°C,
which leads to sedation and respiratory depression. Smaller
doses of meperidine in combination with other drugs (bus-
pirone [14], dexmedetomidine [15], or magnesium [34]) have
therefore been evaluated. The combination of meperidine and
the anxiolytic drug buspirone has been the most effective.
Mokhtarani and colleagues [14] demonstrated synergistic
properties of this particular combination in contrast to other
combinations. The combination of a relatively small dose of
meperidine (0.3 ± 0.1 μg/ml) and a single dose of buspirone
(30 mg orally) was able to lower the volunteers' shivering
threshold to 33.4°C ± 0.7°C.
In the present study, we used meperidine in combination with
skin surface warming and targeted a meperidine plasma level
of 0.9 μg/ml. This combination (meperidine plus skin warming)
has also been tested and used for the induction/maintenance
of mild hypothermia with endovascular cooling in several clini-
cal pilot studies in awake patients. Dixon and colleagues [35]
used a combination of meperidine (75 to 100 mg loading
dose, followed by 25 to 35 mg/hour continuously), skin warm-
ing, and oral buspirone (30 to 60 mg orally) to induce mild
hypothermia (33.2°C core temperature) in 21 patients during
coronary intervention for acute myocardial infarction. They
reported good feasibility with mild shivering in nine patients.
Leslie and colleagues [36] reported that a combination of a
low level of meperidine (target plasma level: 0.4 mg/ml) and
skin warming in 10 patients scheduled for neurosurgery was
insufficient to prevent shivering. However, study results have
also shown a large range of meperidine levels (0.1 to 0.9 μg/
ml) and therefore have to be interpreted with caution. In a pilot
study by De Georgia and colleagues [37], 18 ischaemic
stroke patients were cooled to 33°C using a combination of
meperidine (50 to 75 mg loading dose, followed by 25 to 35
mg/hour continuously), skin warming, and oral buspirone (60
mg). The hypothermia group had a significantly higher inci-
dence of intubations compared to 22 normothermic patients.
The authors stated that it was unclear whether severity of dis-
ease or drug-induced sedation caused the difference. In a
recent feasibility study, Guluma and colleagues [38] used a
combination of meperidine (loading dose 1 mg/kg, followed by
30 mg/hour continuously) and skin warming to induce core
hypothermia (33.8°C) in 10 ischaemic stroke patients and
reported satisfactory results.
However, only in the study by Leslie and colleagues [36] were
meperidine levels measured and sedation assessed with a val-
idated scale; in none of the aforementioned studies was the
interaction between meperidine and skin warming examined.
In contrast, by means of an approach described by Slinker
[29], our present volunteer study is able to demonstrate an
additive interaction between meperidine and skin warming.
Our study results are in accordance with those of previous
studies. Using comparable levels of meperidine (≈ 1 μg/ml),
Ikeda and colleagues [39] showed a decrease of the shivering
threshold to 34.8°C ± 1.0°C (10 volunteers, cooling with intra-
venous cold fluid). The shivering threshold results on the
meperidine day of our study are slightly lower (34.2°C ±
0.2°C), most likely because our volunteers had higher mean
skin temperatures. In a skin warming study by Alfonsi and col-
leagues [21], forced-air warming decreased the shivering
threshold of postoperative patients by ≈ -0.4°C (18 patients,
forced-air warming). Our results show a slightly larger
decrease of ≈ -0.6°C under comparable mean skin tempera-
tures. Skin warming reduces oxygen consumption. Conse-
quently, in volunteers on skin warming days, the threshold
according to the present study's definition of shivering (+20%
increase in oxygen consumption) is reached at a relatively
lower core temperature, which may explain the abovemen-
tioned difference.
We used the combination of meperidine and skin warming in
healthy volunteers only for induction of mild hypothermia. If our
treatment had been applied for more than 24 hours, meperid-
ine toxicity may well have become an important issue.
Repeated doses of meperidine can induce feelings of shaki-
ness, seizures, tremor, mood changes, and muscle weakness.
Norpethidine, a meperidine metabolite, is most likely responsi-
ble [40] and correlates with the side effects of meperidine
Figure 1
Reductions in the shivering threshold versus control Reductions in the shivering threshold versus control. Bars indicate 
means ± standard deviation. Combo, actual effect of skin warming plus 
meperidine; Mep, meperidine; Skin, skin warming; Skin & Mep, calcu-
lated additive effect of skin warming plus meperidine.Critical Care    Vol 11 No 1    Kimberger et al.
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[41]. Patients with renal insufficiency are particularly affected
because they tend to accumulate norpethidine faster [42].
Renal insufficiency therefore has to be considered a relative
contraindication to anti-shivering drug combinations that
include meperidine.
In the present study, core hypothermia was induced by intra-
venous infusion of cold fluid (Ringer lactate, 4°C). This method
has also been used successfully for induction of hypothermia
in several clinical studies in patients with various types of neu-
rologic injuries [43] and in patients after cardiac arrest
[44,45]. Direct core cooling with cold-fluid infusion or intrave-
nous cooling catheters has several advantages over conven-
tional surface cooling. It is faster because heat is removed
directly from the core rather than being required to pass
through peripheral tissues, which insulate the core [46]. Core
cooling can easily be combined with simultaneous skin sur-
face warming. Finally, external cooling can become more diffi-
cult once core temperature is below the vasoconstriction
threshold; this issue does not apply to cold-fluid cooling. How-
ever, despite the surprisingly good tolerance of fluid cooling by
stroke or cardiac arrest patients, cold-fluid cooling may be an
option for induction of hypothermia only, and other techniques
(for example, an intravenous cooling catheter) are necessary
for maintenance of hypothermia. We restricted core cooling
rates to a range of 1°C/hour to 2°C/hour as we had previously
shown that similar rates of skin surface cooling do not directly
affect the shivering threshold and are unlikely to produce
dynamic thermoregulatory responses [25].
A limitation of our study is that it was conducted in young,
healthy volunteers. Results from volunteer studies cannot
always be extrapolated to clinical situations. It is not unlikely
that meperidine-induced sedation–only very mild in healthy
volunteers–may have a bigger impact on patients after cardiac
arrest or stroke.
In the present study, we evaluated sedation with the validated
OAA/S scale [28]. Although this scale does not detect subtle
degrees of sedation, it is unlikely that these subtle changes are
clinically relevant in the context of stroke and other life-threat-
ening conditions. More relevant are respiratory depression and
ensuing hypercapnia, which limit the administration of meperi-
dine in typical ward settings. In our study, end-tidal PCO2 (par-
tial pressure of carbon dioxide) did not increase and no signs
of respiratory depression could be observed.
Conclusion
A combination of meperidine and skin surface warming
reduced the shivering threshold to 33.8°C ± 0.2°C via an addi-
tive interaction and produced only very mild sedation and no
respiratory toxicity. This combination can therefore be consid-
ered a recommendable and feasible regimen for induction and
maintenance of therapeutic mild hypothermia.
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